Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 15/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 15/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716223 | 0.83 | AVPR2 (0.54) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL717597 | 0.83 | AVPR2 (0.54) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL719977 | 0.83 | AVPR2 (0.54) | AVPR2AVPR1ASLC6A2OXTROPRK1 | |
| SCHEMBL4507074 | 0.81 | CNR1 (0.39) | AVPR2AVPR1ACNR1KDM4E | |
| SCHEMBL4502826 | 0.80 | ALDH1A1 (0.43) | AVPR2AVPR1ACNR1KDM4E | |
| SCHEMBL413351 | 0.79 | AVPR2 (0.57) | AVPR2AVPR1A | |
| SCHEMBL4509966 | 0.78 | AVPR2 (0.51) | AVPR2AVPR1ACNR1 | |
| SCHEMBL28812646 | 0.76 | AVPR2 (0.46) | AVPR2AVPR1ACNR1SLC5A2 | |
| SCHEMBL716772 | 0.76 | KDM4E (0.35) | AVPR2AVPR1ACNR1KDM4E | |
| SCHEMBL716773 | 0.76 | KDM4E (0.35) | AVPR2AVPR1ACNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408751-B1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-9687476-B2 | Bisaryl-bonded aryltriazolones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-2539326-B1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2408751-A1 | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051518-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | NAT1, AADAC, TNNI3 | AVPR2 3835/4885AVPR1A 3944/4885CNR1 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.